Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) is scheduled to issue its Q416 quarterly earnings data on Monday, November 21st. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $13.56 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) opened at 31.01 on Friday. The stock has a market cap of $590.28 million, a price-to-earnings ratio of 20.51 and a beta of 0.61. The stock’s 50 day moving average price is $25.53 and its 200-day moving average price is $23.99. Enanta Pharmaceuticals Inc. has a 12 month low of $20.39 and a 12 month high of $34.49.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in Enanta Pharmaceuticals by 295.7% in the second quarter. BlackRock Inc. now owns 4,614 shares of the company’s stock valued at $102,000 after buying an additional 3,448 shares during the period. Riverhead Capital Management LLC increased its position in Enanta Pharmaceuticals by 1,505.1% in the second quarter. Riverhead Capital Management LLC now owns 6,292 shares of the company’s stock valued at $324,000 after buying an additional 5,900 shares during the period. Highbridge Capital Management LLC bought a new position in Enanta Pharmaceuticals during the third quarter valued at $215,000. The Manufacturers Life Insurance Company bought a new position in Enanta Pharmaceuticals during the third quarter valued at $295,000. Finally, American International Group Inc. increased its position in Enanta Pharmaceuticals by 0.9% in the third quarter. American International Group Inc. now owns 11,323 shares of the company’s stock valued at $301,000 after buying an additional 99 shares during the period. Hedge funds and other institutional investors own 65.68% of the company’s stock.

Several research firms have commented on ENTA. Zacks Investment Research lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 11th. JPMorgan Chase & Co. set a $26.00 price objective on shares of Enanta Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $26.29.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

5 Day Chart for NASDAQ:ENTA

Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.